Raphi Levy Sells 17,873 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,873 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00. Following the sale, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,172,340. This trade represents a 16.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Trading Down 6.0%

NASDAQ DRTS opened at $12.76 on Wednesday. The business has a 50 day simple moving average of $10.06 and a 200 day simple moving average of $8.02. Alpha Tau Medical Ltd. has a one year low of $2.87 and a one year high of $14.11. The stock has a market capitalization of $1.15 billion, a P/E ratio of -19.04 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Trifecta Capital Advisors LLC bought a new position in shares of Alpha Tau Medical in the fourth quarter valued at $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the third quarter worth about $62,000. Bank of America Corp DE raised its holdings in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after acquiring an additional 17,500 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new position in Alpha Tau Medical in the 1st quarter valued at about $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on DRTS. Citigroup raised their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 1st. Barclays increased their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Finally, LADENBURG THALM/SH SH upped their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.